Eli Lilly and Company announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has delivered a positive opinion regarding Omvoh as a treatment for adults with active Crohn's disease.
This favorable assessment is grounded in data from the Phase 3 VIVID-1 study, which demonstrated that patients receiving Omvoh showed statistically significant improvements on the study’s primary objectives compared to those given a placebo.
Lilly has sought marketing approvals for Omvoh's use in treating Crohn's disease in several countries, including the United States and Japan, with regulatory decisions anticipated to begin in the first half of 2025.
Omvoh has already received approval for ulcerative colitis treatment in over 40 countries worldwide.
The material has been provided by InstaForex Company - www.instaforex.com
This favorable assessment is grounded in data from the Phase 3 VIVID-1 study, which demonstrated that patients receiving Omvoh showed statistically significant improvements on the study’s primary objectives compared to those given a placebo.
Lilly has sought marketing approvals for Omvoh's use in treating Crohn's disease in several countries, including the United States and Japan, with regulatory decisions anticipated to begin in the first half of 2025.
Omvoh has already received approval for ulcerative colitis treatment in over 40 countries worldwide.
The material has been provided by InstaForex Company - www.instaforex.com